NASDAQ:BOLT - Nasdaq - US0977021049 - Common Stock - Currency: USD
NASDAQ:BOLT (4/28/2025, 8:00:00 PM)
0.3702
-0.02 (-5.08%)
The current stock price of BOLT is 0.3702 USD. In the past month the price decreased by -12.89%. In the past year, price decreased by -66.35%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.73 | 340.25B | ||
AMGN | AMGEN INC | 14.28 | 152.20B | ||
GILD | GILEAD SCIENCES INC | 13.74 | 132.57B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1712.03 | 127.64B | ||
REGN | REGENERON PHARMACEUTICALS | 13.38 | 66.78B | ||
ARGX | ARGENX SE - ADR | 326.83 | 37.92B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.15B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.88B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
NTRA | NATERA INC | N/A | 20.68B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.78B | ||
BIIB | BIOGEN INC | 7.23 | 17.44B |
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 52 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
BOLT BIOTHERAPEUTICS INC
900 Chesapeake Drive
Redwood City CALIFORNIA 94063 US
CEO: Randall C. Schatzman
Employees: 100
Company Website: https://boltbio.com/
Investor Relations: https://investors.boltbio.com/
Phone: 16506659295
The current stock price of BOLT is 0.3702 USD. The price decreased by -5.08% in the last trading session.
The exchange symbol of BOLT BIOTHERAPEUTICS INC is BOLT and it is listed on the Nasdaq exchange.
BOLT stock is listed on the Nasdaq exchange.
8 analysts have analysed BOLT and the average price target is 1.15 USD. This implies a price increase of 209.97% is expected in the next year compared to the current price of 0.3702. Check the BOLT BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BOLT BIOTHERAPEUTICS INC (BOLT) has a market capitalization of 14.19M USD. This makes BOLT a Nano Cap stock.
BOLT BIOTHERAPEUTICS INC (BOLT) currently has 100 employees.
BOLT BIOTHERAPEUTICS INC (BOLT) has a support level at 0.36 and a resistance level at 0.39. Check the full technical report for a detailed analysis of BOLT support and resistance levels.
The Revenue of BOLT BIOTHERAPEUTICS INC (BOLT) is expected to decline by -66.49% in the next year. Check the estimates tab for more information on the BOLT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BOLT does not pay a dividend.
BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2025-05-08.
BOLT BIOTHERAPEUTICS INC (BOLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.52).
The outstanding short interest for BOLT BIOTHERAPEUTICS INC (BOLT) is 0.68% of its float. Check the ownership tab for more information on the BOLT short interest.
ChartMill assigns a fundamental rating of 3 / 10 to BOLT. The financial health of BOLT is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months BOLT reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS increased by 16.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -63.35% | ||
ROE | -110.35% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 48% to BOLT. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 4.88% and a revenue growth -66.49% for BOLT